Visual Grading on Both Planar and SPECT Imaging is the Primary Method for Interpretation of 99mTc-PYP* in Diagnosis of ATTR-CM1
Both Planar and SPECT Imaging1:
- Visually confirm diffuse radiotracer uptake in the myocardium
- Differentiate myocardial uptake from residual blood pool or overlying bone uptake
SPECT imaging is required in all studies to highlight the importance of directly visualizing tracer uptake in the myocardium1
Evaluation for AL amyloidosis is required in all patients undergoing 99mTC-PYP scans for cardiac amyloidosis1
Reproduced with permission from ASNC.2 © 2019 American Society of Nuclear Cardiology.
Multi-Societal Expert Consensus Recommendations (MECR):
- American Society of Nuclear Cardiology (ASNC) with representatives from ACC, AHA, ASE, EANM, HFSA, ISA, SCMR, and SNMMI developed a joint expert consensus document on imaging cardiac amyloidosis1
- Since the original publication (2019), clinical use of cardiac scintigraphy has been extended to populations with lower presence of ATTR-CA1
- Updated (July 2021) to include an addendum to prevent incorrect diagnoses1
Please note that the ASNC Practice Points and ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations were developed by ASNC and multi-societal experts independently of Pfizer, and Pfizer is not responsible for their content.
*99mTc-PYP is not FDA-approved for the diagnosis of ATTR-CM. Please consult individual labeling for risks.
